Form 4: Actuate Therapeutics Director, Jason A. Keyes, Acquires 30,000 Stock Options

Director Jason A. Keyes acquired 30,000 non-qualified stock options in Actuate Therapeutics, Inc. following the company's initial public offering.

Summary

• On August 12, 2024, Jason A. Keyes, a director of Actuate Therapeutics, Inc., was granted 30,000 non-qualified stock options.
• The options were granted upon the effectiveness of the registration statement for the issuer's initial public offering.
• The exercise price of the options is $8.
• The options vest in three equal installments on the first, second, and third anniversary of the grant date, contingent upon continued service.
• The expiration date for these options is August 12, 2034.
• Following the transaction, Keyes directly owns 30,000 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and aligns the director's interests with shareholders. The vesting schedule promotes long-term commitment.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company's long-term success.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the stock options suggests an expectation of continued service from the director.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, especially after an initial public offering.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with the company's success.
• The director is incentivized to contribute to the company's growth and value creation.

Key Dates